company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56465.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56465.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,56465.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,319558.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,313399.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,632957.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-576492.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,907.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,907.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-575585.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-575585.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-575585.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-575585.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,219836096.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219836096.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,219836096.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 15:41:40+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,114331.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,114331.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,114331.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,213896.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,345976.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,559872.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-445541.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,707.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,707.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-444834.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-444834.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-444834.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-444834.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,230300500.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,230300500.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,230300500.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 13:45:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,235365.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,235365.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,235365.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,332806.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,588644.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,921450.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-686085.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1642.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1642.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-684443.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-684443.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-684443.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-684443.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,246902225.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,246902225.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,246902225.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q1,2011-01-01,2011-03-31,2012-05-15 14:48:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,74156.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,74156.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,74156.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,527226.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,636301.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1163527.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1089371.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1734.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1734.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1087637.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1087637.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1087637.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1087637.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,247256013.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,247256013.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,247256013.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q2,2011-04-01,2011-06-30,2012-08-14 16:15:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,91756.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,91756.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91756.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,158969.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,636453.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,795422.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-703666.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1378.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1378.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-702288.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-702288.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-702288.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-702288.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,247686428.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,247686428.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,247686428.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 06:06:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,127907.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,127907.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,127907.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,182219.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,709008.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,891227.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-763320.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1197.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1197.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-762123.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-762123.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-762123.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-762123.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,323600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,323600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248048271.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,110149.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,110149.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,110149.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,218675.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,799072.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1017747.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-907598.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1472.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1472.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-906126.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-906126.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-906126.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-906126.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,260893200.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260893200.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,260893200.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 14:54:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,217135.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,217135.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,217135.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,244557.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,917452.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1162009.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-944874.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1756.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1756.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-943118.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-943118.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-943118.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-943118.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11800000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11800000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11224997.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 20:36:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,134506.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,134506.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,134506.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,427030.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,950823.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1377853.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1243347.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2118.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2118.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1241229.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1241229.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1241229.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1241229.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,12400000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12400000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11963699.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q3,2012-07-01,2012-09-30,2013-11-14 16:36:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,122210.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,122210.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,122210.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,715738.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1162653.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1878391.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1756181.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1654.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1654.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1754527.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1754527.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1754527.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1754527.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11405000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,134000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,134000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,134000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1250000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1398000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2648000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2514000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2522000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2522000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2522000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2522000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,12600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,12312000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 16:10:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,142000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,142000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,142000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1508000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3351000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4859000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4717000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,22000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-20000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4737000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4737000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4737000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4737000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.35
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.35
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13443000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:11:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.35
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,83000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,83000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,83000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1114000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2082000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,194000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3390000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3307000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,51000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-49000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3356000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3356000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3356000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3356000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14135000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 14:48:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,101000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,101000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,97000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2445000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8172000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,610000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11227000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11130000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,170000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-166000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11296000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11296000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11296000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11296000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.75
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.75
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15046000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.75
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,976000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,976000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,563000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,563000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,413000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3385000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6316000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,586000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10287000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9874000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,223000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-219000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10093000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10093000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10093000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10093000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.44
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.44
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23051000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 16:10:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.44
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,775000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,775000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,510000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,510000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,265000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2361000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5309000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,586000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8256000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7991000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,468000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-463000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8454000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8454000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8454000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8454000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25341000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:28:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1276000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1276000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,527000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,527000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,749000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1854000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5440000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,586000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7880000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7131000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,476000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-474000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7605000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7605000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7605000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7605000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28200000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28200000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28533000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q3,2014-07-01,2014-09-30,2015-11-13 21:46:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,798000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,798000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,443000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,443000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,355000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2387000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7127000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,587000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10101000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9746000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,462000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-461000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10207000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1702000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8505000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8505000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8505000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26700000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.32
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26700000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.32
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26679000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.32
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,977000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,977000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,509000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,509000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,468000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2219000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7840000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,586000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10645000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10177000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,439000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-439000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10616000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-178000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10438000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10438000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10438000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36206000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 21:43:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1173000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1173000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,314000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,314000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,859000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3072000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7971000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,349000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11392000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10533000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,442000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-442000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10975000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-17000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10958000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10958000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10958000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36315000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 11:28:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1103000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1103000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,604000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,604000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,499000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4711000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,31312000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,111000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36134000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35635000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,396000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,69275000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,68879000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,33244000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,35323000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2079000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2079000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1140000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-939000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37328.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37328.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31300000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 15:37:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1337000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1337000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,523000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,523000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,814000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10130000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8233000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,111000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18474000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17660000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,375000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,23000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3360000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3712000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21372000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1186000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22558000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-4041000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26599000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-3123000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23476000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36909000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.62
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36909000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.62
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.62
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,988000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,988000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,359000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,359000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,629000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4495000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20777000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,111000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-2740000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22643000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22014000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,307000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5034000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4727000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17287000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17287000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17287000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1637000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15650000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37965000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37965000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38200000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q1,2016-01-01,2016-03-31,2017-05-15 16:05:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,902000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,902000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,295000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,295000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,607000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4220000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,42744000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,111000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1756000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45319000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-44712000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,273000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,515000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,242000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-44470000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-44470000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44470000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1164000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-43306000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46498000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.93
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46498000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.93
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:41:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.93
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2243000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2243000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,418000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,418000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1825000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5267000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10382000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,112000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1687000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14074000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12249000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,236000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,517000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,27193000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,27474000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,15225000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-195000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15420000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,323000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15743000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-147000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15890000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,66193000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.24
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,66527000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,66200000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q3,2016-07-01,2016-09-30,2018-02-26 21:50:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.24
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4019000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4019000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-261000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-261000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4280000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10237000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13272000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,511000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1938000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22082000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17802000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1016000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-5438000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,5520000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-934000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18736000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-701000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,435000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17600000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-323000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17923000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-66000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17857000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50360000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50360000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50300000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4665000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4665000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,816000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,816000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3849000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9092000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11179000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,665000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-3629000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17307000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13458000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1200000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-377000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1577000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15035000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1398000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-1102000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14739000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14739000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-552000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14187000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70302000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:21:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,121910000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,121910000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1085000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1085000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,120825000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10214000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17506000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,656000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-4468000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23908000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,96917000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1208000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-34000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-215000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1457000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,95460000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,57480000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-36527000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1453000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1453000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,3514000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2061000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,76887000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,76888000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,68700000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:07:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6246000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6246000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1311000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1311000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4935000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9961000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14632000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,662000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,12226000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37481000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32546000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1052000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,17000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1028000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33574000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-922000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33596000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33548000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-974000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32574000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,84941000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,84941000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,85700000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 17:00:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3913000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3913000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1226000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1226000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2687000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11039000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17925000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,657000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,1437000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31058000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-28371000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,45009000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-115000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-586000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-45710000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-74081000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1400000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-2105000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-74786000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-74809000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-945000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-73864000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100563000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.73
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,100563000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.73
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,101200000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 16:49:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.73
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4105000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4105000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2177000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2177000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1928000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20102000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29045000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,655000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,33000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49835000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-47907000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2684000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,193000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,18000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2473000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-50380000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-826000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-900000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-50454000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-50454000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-3126000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-47328000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,117021000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.4
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,117021000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.4
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,118300000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 20:46:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6929000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6929000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2346000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2346000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4583000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,22536000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15361000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1035000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-4052000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,11304000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,46184000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-41601000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16975000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,692000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2138000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14145000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-55746000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3148000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-1092000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-53690000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-53715000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-3941000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-49774000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,106150000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,106150000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,106000000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6143000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6143000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2308000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2308000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3835000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25122000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,100917000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,966000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,127005000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-123170000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9080000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,628000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-14188000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-22640000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-145810000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-178000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-897000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-146529000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-146529000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-38458000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-108071000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,122281000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.88
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,122281000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.88
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,122800000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:02:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.88
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6477000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6477000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3281000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3281000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3196000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27772000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24759000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,992000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,34000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53557000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-50361000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9520000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,229000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11002000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-20293000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-70654000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-400000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-1574000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-71828000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-71845000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-15083000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-56762000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,122549000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,132459000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.47
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,123400000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 16:49:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5778000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5778000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5226000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5226000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,552000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25234000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27573000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,991000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,37000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53835000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-53283000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9459000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-39000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11221000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-20719000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-74002000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-221000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-1431000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-75212000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-75212000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-10797000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-64415000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,130800000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140445000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,131500000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 20:46:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13034000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13034000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1422000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1422000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11612000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25429000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,-46370000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,992000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-11161000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,75301000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,44191000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32579000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,35890000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,70000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-711000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-36531000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-69110000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,326000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-7000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-69443000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-69426000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-6606000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-62820000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,132732000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.37
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140514000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,132800000.0
Sorrento Therapeutics Inc,SRNE,549300RH23PRR3M13410,0000850261,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.37
